Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

ACY-7 Oral Administration of Acyline (ACY-7)

This study has been completed.
Merrion Pharmaceuticals, LLC
Information provided by:
University of Washington Identifier:
First received: January 15, 2008
Last updated: May 10, 2011
Last verified: May 2011
Results First Received: January 10, 2011  
Study Type: Interventional
Study Design: Endpoint Classification: Pharmacokinetics Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Healthy
Intervention: Drug: Acyline

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Subjects were recruited via fliers on the University of Washington campus.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Healthy, non-smoking male subjects between 18-50 years of age were recruited. Health was determined by physical exam, medical history intake and laboratory blood tests.

Reporting Groups
Oral Acyline 20 mg dose of GIPET enhanced oral acyline for 7 days

Participant Flow:   Overall Study
    Oral Acyline  
STARTED     4  

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Oral Acyline 20 mg dose of GIPET enhanced oral acyline for 7 days

Baseline Measures
    Oral Acyline  
Number of Participants  
[units: participants]
[units: participants]
<=18 years     0  
Between 18 and 65 years     4  
>=65 years     0  
[units: years]
Mean (Standard Deviation)
  40  (11)  
[units: participants]
Female     0  
Male     4  
Region of Enrollment  
[units: participants]
United States     4  

  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Testosterone Blood Serum Concentration   [ Time Frame: 7 days ]

2.  Secondary:   FSH Blood Serum Concentration   [ Time Frame: 7 days ]

3.  Secondary:   LH Blood Serum Concentration   [ Time Frame: 7 days ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: Dr. John K. Amory
Organization: University of Washington
phone: 206.616.1727


Responsible Party: John K Amory, MD, MPH, University of Washington Identifier: NCT00603187     History of Changes
Other Study ID Numbers: 32716-W
07-7973-W ( Other Identifier: UW Human Subjects Division )
Study First Received: January 15, 2008
Results First Received: January 10, 2011
Last Updated: May 10, 2011
Health Authority: United States: Food and Drug Administration